CareRx Corporation to Host Third Quarter 2025 Financial Results Conference Call on Tuesday, November 4, 2025 at 8:30 a.m. ET
Toronto, Ontario--(Newsfile Corp. - October 24, 2025) - CareRx Corporation (TSX: CRRX) ("CareRx" or the "Company") today announced it will host a conference call to discuss its third quarter 2025 financial results on Tuesday, November 4, 2025, at 8:30 a.m. Eastern Time (ET). The Company expects to report its third quarter 2025 financial results for the period ended September 30, 2025, after market close on Monday, November 3, 2025. Telephone Dial-In Access In
2025-10-24 7:30 AM EDT | CareRx Corporation
HEALWELL AI Completes Week of Business Development and Investor Awareness Activities in the UK Highlighting Its AI-Driven Preventative Healthcare Solutions
HEALWELL AI's management team met with prospective investors, partners and M&A targets as part of a business development roadshow in the UK. HEALWELL also successfully hosted an invitation-only event in London on October 14, 2025, bringing together healthcare leaders, investors, and financial institutions. With strong attendance from UK banks, healthcare providers, and institutional investors, HEALWELL's management shared insights on the growth
Technology, Healthcare and Hospitals
2025-10-23 3:15 AM EDT | HEALWELL AI
Bachem Announces Progress in Building K Start-Up and Expansion of Its Site in Vista, CA
Bubendorf, Switzerland--(Newsfile Corp. - October 23, 202
Biotechnology, Chemical, Healthcare and Hospitals, Pharmaceuticals
2025-10-23 1:01 AM EDT | Bachem Holding AG
FendX Files Provisional Patent for Novel Antimicrobial Nanoparticle Liquid Coating
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2025) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing their technology-based solutions to reduce the spread of harmful pathogens and support a cleaner, safer world, is pleased to announce the filing of a provisional patent application with the United States Patent and Trademark Office. The application, titled "Antimicr
Technology, Healthcare and Hospitals, Health
2025-10-22 6:00 AM EDT | FendX Technologies Inc.
NewOrg Releases Comprehensive Grant Management Guide to Help Nonprofits Streamline Funding and Reporting
Washington, D.C.--(Newsfile Corp. - October 21, 2025) - NewOrg Management System, Inc., a leading provider of cloud-based data management solutions for nonprofits and government agencies, has released a new resource titled Grant Management Software for Nonprofits — Streamline Funding and Reporting. The guide helps nonprofit leaders improve funding allocation, compliance, and reporting with practical strategies grounded in modern, integrated technology. As grant portfolios e
Computer Software, Healthcare and Hospitals, Housing, Aboriginal / Indigenous
2025-10-21 3:00 PM EDT | NewOrg Management System Inc
Adia Nutrition Inc. Appoints Dr. Evan Thomas, MD, PhD, to Drive Adia Med's Specialized Treatment Revolution
Winter Park, Florida--(Newsfile Corp. - October 21, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is excited to announce the appointment of Evan Thomas, MD, PhD, as an Independent Medical Director for its medical division, Adia Med. A renowned radiation oncologist and visionary, Dr. Thomas will oversee clinic practices, including the cutting-edge Autologous Hematopoietic Stem Cell Transplantation (AHSCT) program, finalizing protocols to prepare for patient intake once in-network provider st
Healthcare and Hospitals, Health
2025-10-21 9:00 AM EDT | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 21, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-21 7:45 AM EDT | Phio Pharmaceuticals Corp.
HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical Industry
HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin on October 6, 2025. HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved
Technology, Healthcare and Hospitals
2025-10-21 3:15 AM EDT | HEALWELL AI
Cosmo Pharmaceuticals Receives Regulatory Approval by the European Commission for Winlevi(R) in the EU, Following on the Positive CHMP Opinion
Dublin, Ireland--(Newsfile Corp. - October 21, 2025) - Cosmo Pharmaceuticals N.V. (SIX: COPN), a global leader in AI-powered healthcare and specialty pharma, today announced that the European Commission has granted regulatory approval in the EU for Winlevi® (clascoterone 1% cream) for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years, with usage in adolescents limited to facial application. This formal approval came following on the po
Healthcare and Hospitals, Health
2025-10-21 1:36 AM EDT | Cosmo Pharmaceuticals N.V.
Adaptimmune Announces Delisting from Nasdaq
Pennsylvania and Oxford, United Kingdom--(Newsfile Corp. - October 20, 2025) - Adaptimmune Therapeutics plc (NASDAQ: ADAP) ("Adaptimmune" or the "Company") today announced that the Company's Board of Directors (the "Board") has determined to initiate the delisting of its American Depositary Shares ("ADSs"), each representing six ordinary shares, from The Nasdaq Capital Market ("Nasdaq") and deregistration under Section 12(b) of the Securities Exchange Act of 1934, as amended (th
Biotechnology, Healthcare and Hospitals
2025-10-20 7:40 AM EDT | Adaptimmune Therapeutics PLC
MyndTec Inc. Completes Sixth Tranche of Non-Brokered Private Placement
Mississauga, Ontario--(Newsfile Corp. - October 16, 2025) - MyndTec Inc. (CSE: MYTC) ("MyndTec" or the "Company"), a neurological treatment and rehabilitation medical technology company, is pleased to announce that it has closed the sixth tranche of its non-brokered private placement previously announced on January 30, 2025 (the "Offering"). The sixth tranche of the private placement consists of 263,428 Units of the Company (the "Units") at a price of $0.20 per Uni
Technology, Healthcare and Hospitals, Health
2025-10-16 6:00 PM EDT | MyndTec Inc.
Conexeu Sciences Closes Maximum $5M Reg CF Financing
Reno, Nevada--(Newsfile Corp. - October 16, 2025) - Conexeu Sciences Inc. (the "Company" or "Conexeu") a biotechnology company revolutionizing tissue regeneration, is pleased to announce the completion of its $5 million Regulation Crowdfunding (Reg CF) financing. Conexeu secured commitments in excess of $5 million in less than two weeks from the date of launching the financing through the Equifund platform.
Healthcare and Hospitals, Pharmaceuticals, Health
2025-10-16 9:01 AM EDT | Conexeu Sciences Inc.
Adia Nutrition Paves Way for Nasdaq and New Investors Through SEC Form 10 Submission
Winter Park, Florida--(Newsfile Corp. - October 14, 2025) - Adia Nutrition Inc. (OTCQB: ADIA) is thrilled to announce a major milestone in its growth journey. The Company has engaged an independent public accounting firm and securities counsel to prepare and file its Form 10 registration statement with the U.S. Securities and Exchange Commission (SEC). This filing marks a significant step beyond OTC reporting and positions Adia as a fully reporting public company under the Securities Exchange
Healthcare and Hospitals, Health
2025-10-14 9:00 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces Closing of Up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - October 9, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share. In addition, in a concurrent private placement, Envoy Medical issued
Biotechnology, Healthcare and Hospitals
2025-10-09 4:05 PM EDT | Envoy Medical, Inc.
Global Hemp Group Applies for Partial Revocation Order and Announces Proposed Financing
Vancouver, British Columbia--(Newsfile Corp. - October 9, 2025) - Global Hemp Group Inc. (CSE: GHG) (OTC Pink: GBHPF) (FSE: GHG0) ("GHG" or the "Company") announces that it has applied to the British Columbia Securities Commission ("BCSC") for a partial revocation order (the "Partial Revocation Order") in connection with the failure-to-file cease trade order ("FFCTO") issued against the Company on April 15, 2025, for failing to file certain continu
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Cannabis
2025-10-09 9:29 AM EDT | Global Hemp Group Inc.
Discovery Senior Living Enters Management Agreements with Diversified Healthcare Trust, Deepens Industry Leadership Position Adding a 42 Community, Multi-State Portfolio
Bonita Springs, Florida--(Newsfile Corp. - October 8, 2025) - Discovery Senior Living ("Discovery" or the "Company") and its affiliated subsidiaries, one of the most trusted and the largest privately held senior housing operators in the U.S., is pleased to announce it has entered into multiple management agreements with Diversified Healthcare Trust ("DHC") (NASDAQ: DHC) to operate a 42-community senior living portfolio. The scale and complexity of this transaction underscore Discovery's posi
Healthcare and Hospitals, Real Estate, Housing
2025-10-08 5:43 PM EDT | Discovery Senior Living
Adia Nutrition Inc. Delivers Explosive Third Quarter Growth: Revenue Surges Over 100% from Prior Quarter, with Remarkable Profit Margin Exceeding 20%
Winter Park, Florida--(Newsfile Corp. - October 8, 2025) - Adia Nutrition Inc. (OTCQB: ADIA), a trailblazer in umbilical cord stem cells and exosome sales and therapies, today announced phenomenal preliminary financial results for the third quarter ended September 30, 2025. The company achieved a monumental revenue increase of more than 100% compared to the second quarter, while posting an extraordinary profit margin exceeding 20% for the quarter. This blockbuster performance cements Adia Nut
Healthcare and Hospitals, Health
2025-10-08 8:30 AM EDT | Adia Nutrition Inc.
Envoy Medical Announces up to $16 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
White Bear Lake, Minnesota--(Newsfile Corp. - October 8, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical"), a hearing health company focused on developing innovative, fully implanted hearing solutions, today announced it has entered into definitive agreements for the issuance and sale of an aggregate of 3,007,524 shares of its Class A common stock at a purchase price of $1.33 per share, in a registered direct offering priced at-the-market under Nasdaq rules. In addition, in a
Biotechnology, Healthcare and Hospitals
2025-10-08 7:00 AM EDT | Envoy Medical, Inc.
medmix Wins One of the Largest New Beauty Businesses in Company History and Strengthens Position in Key Global Beauty Markets with Facility Extensions
Baar, Switzerland--(Newsfile Corp. - October 8, 2025) - medmix AG Neuhofstrasse 20 CH-6430 Baar communications@medmix.com www.medmix.swiss MEDIA RELEASE DOWNLOAD MEDIA RELEASE medmix Wins One of th
Technology, Construction / Building, Healthcare and Hospitals, Household / Consumer / Cosmetics
2025-10-08 3:12 AM EDT | medmix AG
BioMark's Liquid Biopsy Platform Selected for Holistic German Lung Cancer Screening Trial
Vancouver, British Columbia--(Newsfile Corp. - October 7, 2025) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that the company has been invited to participate in the landmark HANSE lung cancer screening trial in Germany. This strategic clinical collaboration with Prof. Dr. Jens Vogel-Claussen at Medizinische Hochschule Hannover, Prof. Dr. Martin Reck at
Technology, Biotechnology, Healthcare and Hospitals
2025-10-07 8:30 AM EDT | BioMark Diagnostics, Inc.